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Chapter I I
Chaptcr l. General introductiort.
Malignant tumours of the testis are mainly found in the third and Íburth decade of l i fè, a
period in rvhich nrost lnen are highly sexually active. To date more than ninety per cent of
the testicular cancer patients can be cured by combined modality treatment consisting of
surgerv. chernotherapy, and radiotherapy. With the improved prognosis there is a growing
awareness about the quality of l i Íè of these young men who are expected to enjoy a long-
tenn and clisease-Íl'ee lif'e after completion of curative treatment. Although post-treatlnent
sexual functionrng is a very relevant aspect of the quality o1' l i fè, only a very small amount
of inÍirrrnation is available about the sexual sequelae of the current therapies for testicular
callcer. ln this thesis, the impact of the different treatment rnodalit ies on organ systents
important lbr normal sexual functioning was studied.
Chapter 2. Current concepts about testicular cencer.
Malignant testicular germ cell tumours are histologically divided into seminomas and
nonsenrinomas. The clinical behaviour of these two tumour types requests a rather different
treatnlent approach which is also based on the results of post-orchidectomy staging
investigations. Following orchidectomy, patients with stage I nonseminomas wil l be
surveil led at the outpatient clinic. This surveil lance policy consists of f iequent physical
check-ups. detection of elevated tumour markers, and cornputerized tomography scanning
ol the n.rost l ikely sides of metastases amor.rg which the retroperitoneum and lungs. Patienls
with disseminated nonseminomas (stage II to 1V) wil l receive ft lur courses of cisplatin
(Platinol.) combined with vinblastine and bleomycin (PVB) or etoposide instead of
vinblastine (l lEP), and, if necessary, resection of post-chemotherapy residual
relrclperitoncal turnour mass (RRRTM). Patients with serninomas (stage I-l lA) wil l be
treated u'ith low-dose external beam raciiotherapy to the retroperitoneal nd ipse para-il iacal
lyniphatics. As in nonseminomas, patients with disseminated seminomas wil l also receive
PVII or l lEP. ln recent years several studies have been conducted concerning late toxicit ies
aÍter' l)VB or I3EP-regimens Íirr testicular cancer, such as neurotoxicity, vascular toxicity,
ancl lerti l i ty irnpairment. Especially angiopathy is rather common ïbllowing PVB or BEP,
and is nrainly expressed by the Raynaud's phenomenon (the syndrome of digital ischaemia).
Also clinical signs of neuropathy (acral paraesthesia) re fiequently present Íbllowing PVB
or BL,P. Lnpaired spermatogenesis results Íiom treatment-induced gonadal dysÍunction, but
Leydig cell dysf'uttction and hormone alterations seem to appear in more than 50 per cent of
the patients. In testicular cancer patients, these treatment-related toxicit ies on blood vessels,




Chaptcr 3. Physical aspects of nmle sexual respoilse.
To untler.stand rvhy testicular cancer and its treatment may aÍÍbct sexual Íunctioning,
currcnt basic conccpts aboul the male scxual response and the physiological phenornena
contrrbuting to the subjectivc cxperiences during sexual response are sunrrnarized in this
[ihapte r'. Sexual r.e sponse re Íe rs to changes rvithin the bocly and rnclre specifically to
alteralious within thc genital organs during sexual arousal. The physiological concepts are
out l ined in thc "scxual  response cyc lc" . ' l 'h is  cyc lc  is  d iv ided into f ive phases:  l ib ido,
serur l  l r .ousal .  ercct ion,  orgasn)  and e- jaculat ion.  L ib ido involves physio logic ,  cogni t ive.
and bchuvioral corlponents. I lunlones such as testosterone and oestradiol are required l irr
nolmal lrbiclo. Scxual arousal is accompanied by a sense of excitement and pcnile erection.
Penile er.ection is a rnainly parasympathetic event. ' l 'hese parasympathetic nerves enter the
pelr  ie  p lcxus at  th t :  Icvel  of  52 S.1.  run 1o sacra l  p lerus and f ina l ly  to  the pudendal  nerve.
Impr.rlscs r ia this ner\'ous route rvil l  cause at least a six-l ir ld blood llorv increase n'ithin the
cavcrnosul artcries. Within the cavernosal bodies. nitric oxides acts as neurotransmitter and
its acliorr is testostcrone dcpcndent. Orgasm is acconipaniecl hy ejaculation. Impulscs
condueted i ia thc retroperitoneal located sympathetic nervcs cause snrooth muscle
contraeti()ns of thc det-erent dlrcts which propels senlen into the prostatic urethra (scnrinal
enission). Concornitant syrnpathetically-induced contraction ol'the bladder neck seminal
pas-sase into the bladder. It is suggested that pelvic l loor contractions, that contribute to
pro.jccti ie c' jaculation. are part of the nrotor componcnt of cllgasnr. ' Iestosterone positivelr '
rnÍlucrrces dischar-gc of pelvic tutitoneuron pool.
I r r  conclus ion,  in  sex the whole body is  involved in an in terp lay o l  cmot ional  and
souralic l)rocesses. I)iÍÏerent b0dy-systcms uch as thc horrnonal. vascular, and nervous
svsteurs c losel r  in te lact  in  nra le sexual  response.  In test icu lar  cancer pat ients.  organrc
biologicul t. iclors rrral, cclntribute to sexual dystunctioning in a substantialh cxtent.
Chaptr:r J. I'-antasie,s and facts of the testes.
It is generally assunred that thc testcs, i.c. testostcrone, play an irnportant role in nrale
serual  bc l rav iour . ' l 'h is  assurnpt ion is  s t rengthened by the manl ' l i rn tas ies,  my' ths and bel ie l .s
tir ir l \uf rour)cl the testes. The testes sy'rntrolize masculinity. serual potencl. ' and Íerti l i ty.
' l ' ircrelirre. 
rnanv uren experience hemicastration as an "assaull" on their viri l i ty. In this
Cihaptel ar.cliaic lantasies about testicular l irrrction in relation 1o potency arc reluted by thc
currenl lacts. I lased on tl lc ancient empirical cxperience that caslratiOn leads t0
deteriorlt ion of sexual tunction, man has sought alter the "magic" of the testes in relation
to rir i l i ty and sexual potency. This resulted in the discovcrry of tcstostetone. Currently, it is
known that testosterone plays only a minor role in male sexual behaviour and subnorrnal
lestosterone levels are rarely the main cause of sexual problerls. Not only loss oi sexual
potencv is feared b1' hemicastrated mcn but also deterioration reproductive tunction,
Because of the pituitary-gonadal feed-back mechanism, the loss of clne testis rvil l  have
hardly uny influcncc on sperm production.
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Chapter 11
In conclusion, although (hemi)castration will leave the endocrine and exocrine function
nearly unaÍ1'ected, deeply settled cultural and historical pressure may cause psychological
problems is patients who have to accept the loss of a testis. Therefbre it seems worthwhile
when one approaches a patient who faces hemicastration to examine his fantasies and
beliefs about the sexual consequences of losing a testis.
Chapter 5. The sexual sequelae of testicular cancer.
The literature was studied to obtain information about the prevalence rate and types of
sexual dysfunctioning in relation to the different treatment modalities for testicular cancer
and to gain insight into the possible contributing organic factors. According to the literature
the prevalence rate of post-treatment sexual dysfunction varies fiom 10 to 50 per cent,
depending on the type of dysfunction and investigation methods. Decreased plasma
testosterone levels due to orchidectomy, chemotherapy, and scatter radiation may
negatively inÍluence libido, sexual thoughts as well as spontaneous nocturnal penile
erections. However, in most patients compensatory elevated LH-levels will usually
maintain testosterone within the (sub)normal ranges. Chemotherapy-induced
hyperprolactinaemia may suppress pituitary LH and, in this way, may also cause
hypogonadism. Chemotherapy-induced vascular and nerve damage may account for erectile
ilysÍunction and decreased intensity of orgasm but no data are available about this matter.
Because of injury to the sympathetic ganglia and hypogastric nerve fibres, retroperitoneal
lympli node dissection (RPLND) may result in loss of antegrade ejaculation. Primary
bilateral RPLND causes ejaculatory failure in 45 to 97 per cent of the cases. Tcl preserve
ejaculation prirnary unilateral RPLND and nerve-preserving procedures have been
developed. Following chemotherapy however, nerve-sparing procedures may be technically
difficult clue the presence of gross tumour mass and the inflammatory reaction resulting
from chemotherapeutic response. Therefore, resection of only post-chemotherapy residual
retroperitoneal tumour mass (RRRTM) is performed in some centres. The prevalence rate
of ejaculatory dysfunction following RRRTM is unknown and may depend on volume and
location of tumour mass. Radiation associated impotence has been linked to damage of
small bklod vessels. After pelvic irradiation for prostate cancer, erectile dysfunction has
been reported in 25 to 47 per cent of the patients, and decreased penile blood pressure as
well as decreased arterial diameters have been demonstrated following radiotherapy.
Although in seminoma patients only the para-aortal and ipse-iliacal lymphatics are
irradiated, scatter radiation may compromise the feeding branches of the penis resulting in
suboptimal erection. Published data are missing about this matter.
In conclusion, there is lack of information about the sexual sequelae of the current
therapies Íbr testicular cancer. In almost all reviewed studies no correlation had been made
between treatment modalities and sexual dysfunction, and in none of the studies an attempt




Chapter 6. Sexual dysfunctiort itt ttonseninonm íesticular cancer patients is related to
c h e ntot h e rapy - irtdu c e d angiopatlry.
Acletluate intbrntation is tacking about the incidence o1' post-treatntent sexual
dt'sfunctionirtg. attd the contlibution of chemotherapy-induced angio- and neuropathy with
resarcl to serual dysfunction has been neglected so lar. The aim clÍ the study was to
establish sexual t ly'slunction ft l l lowing cisplatin-based chemotherapy Íbr disserninated
testicuLrr cancer and to dctermine if chemotherapy-induced angiopathy (Raynaud's
phcttortrctton) and neuropathy (acral paraesthesia) were related to erecti le- and e'jaculatory
dvslurtction. A cluestiontraire:rssessing l()st-trcatment sexual lunctioning was sent to 255
lcstictt lal cattcer sur', ' ivors treated betrveen 1980-1994. Frequencies <t1'sexual dyslunctions
in patients trcated with chernotherapy, r.vith or without additional retroperitoneal surgery,
\\ 'ere c()lrpared to those treated with clrchidectomy and'surveil lance'. Sexual dysfunctions
t'ele rc' lated to cltemotherapy-induced Raynaud's phenornenon and paraesthesia.' lhe
resp ( )nse  ra t c  $as  8 .1% (N :215 ) ,56  pa t i en t s  (26%)has  been  t rea ted  by ' s r " r r ve i l l ance ' , 42
(209i ) ltad rece ived cltenrotherapy only and the rernainiug 111 (51%) had chemotherapy
attd adtl it ional retroperitoneal surgery. Overall, the loss of l ibido rvas reported by 19%,
decrcased arousal  b5,  1 l%, erect i le  dystunct io l  by 12%, decreased intensi ty  of  orgasm by
2092. rrnd t ' iaculatorl '  dyslunction by 28'/o. Absence ol ejaculation rvas only reported by
palicttts u'ho had additional surgery. Compared to those on surveil lance, sexual
dyslurtctiorts \\ 'ere nx)re o1len rcported by chomotherapy-treated patients. ln these patients,
Ratr r rud 's  p l tenor lenon and acra l  paraesthesia were repor ted in33% ant l  2 l% re-spect ive ly .
[ 'atie nts u ith Ruvnaud's phenomenon conrplained nlore l iequently about erecti le
dy slirnction (29(/; ) cornpared to those rvithout this phe nome non (8ri,) (p < 0.05).
I)alaesll iesia \\ 'clc n()t lelated to any aspect of sexual response.
lrr conclusion. cornpared to those treated rvilh orchidectorny only, testicular cancei'
paticnts u'ho lrad additional chernotherapy reported rnore Íiequently sexual dysfunctions.
[]urthelnrore. crccti lc dysÍunction was clearly related to chcnrotherapy-inducecl Raynaud's
pliencrntenort. suggesting treatment related angiopathy underlies this clysfunction. -l 'hese
Íirtcl ings usgest ltat erecti le dvsÍunction is caused by chemotherapy-induced angiopathy,
rr'he reas c' jaculatorv dysfunction is t l ie result o1' surgery-inducecl damage oÍ' the
retroperitoneal nerve fibres.
Chapter 7. Ob.jective and subjective effects of testicular cancer treotnrcnt on serual
functiott.
Paticnts with disseminated nonseminoma can expect long-term, discase-fiee, survival alier
olcli idectorny fir l lclrved by Íour courses cisplatin combined with etoposide and bleomycin
(BIIP). I lorvcver, as has been demonstrated in Chapter 6, posttreatment sexual dystunction
is l 'requently' reported by these survivors. In a prospective study, BEP-induced alterations in
pituitary gonadal axis and (penile) bkrod flow were related to sexual dysfunction. Since
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included. Patients treated with BEP (n:10) were compared to those treated with
orchidectomy alone, who served as controls (n:11). In all patients, sex-hormone assays
were determined at three time lapses: just prior to orchidectomy (tr) and respectively 6 (tr)
and 12 months (t.,) thereafter. To assess the effects of BEP on penile flow and inflow traject
of the penis, duplex-ultrasonography of the cavernosal arteries and arterial femoral bed was
prefbrmed befbre and after injection of papaverine. Moreover, patients were asked about
symptoms of BEP-induced angiopathy. Also at tr, t2, and t, sexual functioning was assessed
by means of a questionnaire, and after one-year follow-up (t.,), a visual erotic stimulation
(VES) test was perfbrmed to measure the ability to achieve adequate penile erection during
sexual arousal.
In contrast to the surveillance-group, BEP-treated patients had increased FSH (4.6
vs 26.5 U/l) and LH (1.4 vs 8.2 U/l) levels, and decreased testosterone l vels (21.1. vs
14.7 nmol/l) at six months compared to base-line. One year after the BEP-schedule
decreased plasma LH and physiological testosterone levels were found reflecting
compensated Leydig cell dysfunction. There was no difference in papaverine-induced
changes of cavernosal blood flow velocities of BEP-treated patients compared with controls
(tr vs t3). Befbre treatment, none of the patients had symptoms of angiopathy. However, a
third of the BEP-treated patients reported Raynaud-like symptoms after completion of the
BEP schedule. In these patients, cavernosal blood flow was not comprised compared to
those without Raynaud. Libido loss and erectile dysfunction were more frequently reported
by BEP-treated patients. But one year after treatment he majority reported a satisfying sex-
life, and visual erotic stimulation resulted in a rigid erection in nearly all participants.
Moreover, plasma testosterone levels and cavernosal blood Ílow velocities were not related
to the reported erectile problems.
In conclusion, this prospective study demonstrates that sexual morbidity in testicular
cancer patients is considerable following the confrontation with testicular cancer, but
signiÍicant improvement can be expected within one year following treatment. Four courses
of cisplatin in combination with etoposide and bleomycin (BEP) induce no permanent
endocrinological changes, and recovery of testicular function can be expected. Although the
BEP-regimen is related to angiopathy, cavernosal blood flow does not seem to be affected
at all, even in patients with Raynaud-like symptoms. These findings and the normal penile
rigidity tluling visual erotic stimulation test suggest hat sexual dysfunction following BEP
is contributed to rather psychological factors than BEP-induced organic changes.
Chapter 8. Sexual functioning after multimodality treatment for disseminaÍed
nonseminomatous testicular genn cell tumour.
In this study, sexual functioning was established after chemotherapy for disseminated
nonseminomatous testicular germ cell tumour (NSTGCT) and the impact of resection of
post-chemotherapy residual retroperitoneal tumour mass (RRRTM) was evaluated. One
hundred and Íifty-five consecutive patients treated with chemotherapy for disseminated
NSTGCT were questioned about their sexual functioning. The patients were divided in two
r49
Stttt tnru-n*
subgnrups: patier)ts trcated with or r.vithout RRRTM. Volunre and location (divided into leti
para aortal (LPA) or riglrt para-caval/inter aorta caval (RPC)) of the resccted tumour mass
\\ 'erc related to absence of ejaculation as wcll as decreased semen amount. In addition.
l ibido. amusal, erection and orgasm were related to ejaculatory dysfunction. F-orty-three
pat ients 127.7 ' )L)  were t reated wi th chemotherapy only,  and 112 (72.3%) had addi t ional
RRRI 'M Ovcral l .  2241Í t  repor ted krss of  l ib ido,  14.1% decreased arousal ,  i6% erect i le
dvslur ic t ion.23. l7 l ,  decleased orgasmic in tensi ty ,  17.47o decreased semen anrount ,  and
1E.791 conrplete absence of antegrade .jaculation. With exception of absence of ciaculation,
scxual dvslirnctions u'ere repurted in sirnilar f icquencics in both treatment subgnrups. In
the RI{R'f\I subsroup. 25.9'/c of tht: patients had complete ahsence of ejaculation. I 'hc
other  ser i r l l  dy 's luncl ions *ere nei ther  e lated to decreased semen amount  nor  to completc
abscnce rrl ejrLculation. ' l 'he nrean volume ilf resected turnour rnass \\ras l i ighcr (9-5 crnr) irr
l)aticnts uit ir absence of e.jaculation than in those uithout (-10 cnrr.). und patients with RPt'
Iocutcd tunrour  (3-+.5 ' / ; )  rcpor ted rnore o l ien ahsence o1 'c ' jaculat ion than those r i i th  l .PA
l o c ; 1 1 . ' , 1  t l l n r r l l n  1 l t r . 7 t ,  . 1
Irr corrclusion. in paticnts treated fbr disseminated NSTGCT, post chemotherapy
sexual rnor.bidit,v cannot be neglected. Except for loss of antegrade ejaculation, sexual
clvslunctions are l lot related to rcsection of post-chemotherapy residual retropeÍitoneal
tuntour muss. A high volume of turnour mass and a right para-caval/intcr aorta-caval
Iocation predispose to loss of antegrade jaculation.
Chapter 9. ()isplatin-based chentotherapy changes the incidence of bilateral lesticular
cQncer.
ln thc prcvious ( 'haptcrs the eff i 'cts of treatnrent un sexual functioning was studied in
l)at icl t ts r l ,r th uni latelal test ic:ular cancer. ( 'ornpared to the norÍnal l)utch rnales, uni lateral
les l i cu lu r  car rccr  p i i t ien ts  a re  a t  r i sk  to  deve lop  a  sec< lnd  p l in ra rv  tun iour  in  the i r
e ontralatelal (est is. IJecause thc exact r isk is unknt)w11. the incidetrce of a contralateral
rest iuLl l i i l  derelopurcnt $'as sludied and ceimparcd tci  test icular tulnouÍ dcvelclpment in
rrulurel uge-adjustcd Dutch nlale populat ion. The incidcnce of a second primary test icular
lLiut()r. l r  lnronu ló-i  consecutive patienls r,r ' i th nonseminomatous test icular germ cel l  cattcer
* r rs  rs r r ib l i shcd  an t l  le l l ted  to  p rev ious  thcrapy .  A f ie r  a  to ta l  o1  2 ,403 person-ycar .s  a t  l i sk .
l l  n rcn  (3  per  ccn t )  t le r , ' c loped a  cont ra la te ra l  tuurour ,  wh ich  is  a  s ix ty - fb ld  o t ' thc  expec ted
inc ic lencc ' fa tc  o1  tes t i cu la r  cancer  in  agc-ad . jus ted  L)u tch  nren .  A  th ree  t imes lower
incidence rate ol l  contralateral test icular turnour was Í irund in the chernotherapy-subgroup
cornpelcci u' i t l ' r  those on survei l lance, which rnay indicate that cisplat in-based chenrotherapy
el int inatcs car.cinorna in situ or early test icular cancer within thc contralateral tcst is.
In conclusion, in patients with a nonseminoma testicular germ cel l  tumour, the
incidcnce contralateral tumour is 3 per cent. Compared to healthy Dutch men.
nonsenrinonur patienls have a relat ive r isk of 60 to develop a contralateral test icular tumour.
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Chapter I0. Sexual functioning in testosterone-supplemented patients with bilateral
testicular cancer.
Treatment of bilateral testicular cancer will inevitably result in total castration. To mainrain
sexual Íunctioning and male sex features, men castrated fbr bilateral testicular cancer
receive intrarnuscular (i.m.) testosterone-injections 1SutanonR;. The effects of i.m.
testosterone on sexual functioning were studied in seven patients castrated for hilateral
testicular crncer. Se.lf report data about sexuality, hormone analysis, nocturnal penile
tumescence and rigidity (NPTR) as well as visual erotic stimulation (VES) measurements
were determined at three intervals: one day after injection (t,), in between (tr), and just
prior to the next injection (t.,). Three out of the seven patients reported decreased arousal as
well as erectile dysf'unction, but both problems could not be objectified during VES and
NPTR. At t,, the rnean plasrna testosterone was a six-tbld of that at t3 35.8 (SD 7.8) versus
6.0 (SD 2.5) nm<-rlll). At t, , Íbur patients had testosterone levels above the normal limit
(>35 nmol/l), whereas at t2 and tr testosterone levels were below l0 nmol/l in respectively
three and six patients. No relationship was found between testosterone levels and the self--
reports about sexual functioning including the results of NPTR- and VES measurements.
However, at the end of the injection interval three men reported excessive sweating, hot
flushes and heat intolerance.
In conclusion, although testosterone-supplemented bilateral testicular cancer
survivors have plasma testosterone levels outside the normal limits at many occasions, their
sexual problems are not related to these testosterone fluctuations. The same accounted fbr
erotic stimulated and spontaneous nocturnal erections.
Conclusions
In general, the following main conclusions can be drawn from the thesis. Patients treated
for testicular cancer Íiequently suffer from sexual dysfunction. Until recently, little
research has been done concerning the aetiology of posttreatment sexual morbidity, and
nearly all studies, so fàr, have focused on psychological aspects of sexual dysfunction.
'fhe 
current treatment modalities are potentially toxic for blood vessels, nerves and
testes, and therefore, normal sexual function may be negatively affected. Patients treated
with chemotherapy reported more frequently sexual dysfunction compared to those treated
with orchidectomy alone. Erectile dysfunction is related to chemotherapy-induced Raynaud-
like symptoms, suggesting that chemotherapy-related angiopathy also forms the basis of
erectile dysÍunction. However, with the use of pharmaco-duplex ultrasonography, no blood
Í1ow changes in the penile vascular bed could be established beÍbre and after chemotherapy.
Although cisplatin-based chemotherapy causes temporarily Leydig cell
insuÍÏiciency, subnormal plasma testosterone levels have no influence on distinct phases of
rnale sexual response. Total absence of antegrade ejaculation is only reported by patients
treated with resection of postchemotherapy retroperitoneal tumour mass. A large tumour
volume and right paracavallinter aortacaval tumour location predisposes to ejacfulatory
151
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dysfunction. Ejaculatory dysfunction is not related to other types of sexual dysfunction.
In patients with a unilateral nonseminomatous testicular germ cell tumour, the
incidence of a second primary (contralateral) tumour is three per cent, which is sixty times
the expected incidence rate in a similar-aged healthy Dutch males. A three times lower
incidence rate of a contralateral testicular tumour was found in the chemotherapy subgroup
compared to those on surveillance, supporting the hypothesis that cisplatin-based
chemotherapy may eradicate carcinoma in situ or early testicular cancer. The treatment of
bilateral testicular cancer results in total castration, and patients are treated with
testosterone-injections postoperatively. These testosterone-injections result in major
fluctuation of the plasma testosterone level but sexual dysfunction is not related to sub-
physiological testosterone levels.
The direct somatic consequences of the treatÍnent of testicular cancer play only a
minor role in posttreatment sexual dysfunction. Psychological factors as well as general
malaise and fatigue probably play a more determining role. The supply of information and
counselling may contribute to the improvement of quality of life after treatment of a
malisnant testicular tumour.
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